Pay in 4 interest-free payments of $6.99 Learn more
Ships within 48 hours · Estimated delivery Aug 18 - Aug 23
10.3410/f.735450328.793558526 Lancet
While acknowledging that GLP-1 agonists have revolutionized the way diabetes and obesity are managed and play an important role in the care of many patients, the commentors ask, Will healthcare professionals prescribe these medications because they lead to a decreased risk of AMD
The article names pre-treatment weight, metabolic rate and comorbidities as influences on the trajectory after discontinuation, and says provider assessment is essential before tapering begins
In India alone, over 100 million people struggle with obesity, with particularly high prevalence rates observed in states like Kerala, Tamil Nadu, Punjab, and Delhi
US$ 25.59
US$ 29.38
US$ 22.88
US$ 26.12
US$ 23.87
:max_bytes(150000):strip_icc()/VWHealth-Could-GLP-1Drugs-Reduce-Obesity-Related-Cancers-in-the-Future-3-7d602ab39c0448ddb00cd91b06be2a84.jpg)
